---
input_text: Restoration of BDNF, DARPP32, and D2R Expression Following Intravenous
  Infusion of Human Immature Dental Pulp Stem Cells in Huntington's Disease 3-NP Rat
  Model. Huntington's disease (HD) is a neurodegenerative inherited genetic disorder,
  which leads to the onset of motor, neuropsychiatric and cognitive disturbances.
  HD is characterized by the loss of gamma-aminobutyric acid (GABA)ergic medium spiny
  neurons (MSNs). To date, there is no treatment for HD. Mesenchymal stem cells (MSCs)
  provide a substantial therapeutic opportunity for the HD treatment. Herein, we investigated
  the therapeutic potential of human immature dental pulp stem cells (hIDPSC), a special
  type of MSC originated from the neural crest, for HD treatment. Two different doses
  of hIDPSC were intravenously administrated in a subacute 3-nitropropionic acid (3NP)-induced
  rat model. We demonstrated hIDPSC homing in the striatum, cortex and subventricular
  zone using specific markers for human cells. Thirty days after hIDPSC administration,
  the cells found in the brain are still express hallmarks of undifferentiated MSC.
  Immunohistochemistry quantities analysis revealed a significant increase in the
  number of BDNF, DARPP32 and D2R positive stained cells in the striatum and cortex
  in the groups that received hIDPSC. The differences were more expressive in animals
  that received only one administration of hIDPSC. Altogether, these data suggest
  that the intravenous administration of hIDPSCs can restore the BDNF, DARPP32 and
  D2R expression, promoting neuroprotection and neurogenesis.
raw_completion_output: |-
  primary_disease: Huntington's disease

  medical_actions: Intravenous infusion of human immature dental pulp stem cells; Immunohistochemistry quantities analysis

  symptoms: Motor disturbances; Neuropsychiatric disturbances; Cognitive disturbances

  chemicals: 3-nitropropionic acid (3NP); BDNF; DARPP32; D2R

  action_annotation_relationships: Intravenous infusion of human immature dental pulp stem cells TREATS motor disturbances IN Huntington's disease; Intravenous infusion of human immature dental pulp stem cells TREATS neuropsychiatric disturbances IN Huntington's disease; Intravenous infusion of human immature dental pulp stem cells TREATS cognitive disturbances IN Huntington's disease
prompt: |+
  From the text below, extract the following entities in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  Intravenous infusion of human immature dental pulp stem cells TREATS cognitive disturbances IN Huntington's disease

  ===

extracted_object:
  primary_disease: MONDO:0007739
  medical_actions:
    - Intravenous infusion of human immature dental pulp stem cells
    - Immunohistochemistry quantities analysis
  symptoms:
    - Motor disturbances
    - Neuropsychiatric disturbances
    - HP:0100543
  chemicals:
    - CHEBI:16348
    - BDNF
    - DARPP32
    - D2R
  action_annotation_relationships:
    - subject: Intravenous infusion
      predicate: TREATS
      object: motor disturbances
      qualifier: MONDO:0007739
      subject_extension: human immature dental pulp stem cells
    - subject: Intravenous infusion
      predicate: TREATS
      object: neuropsychiatric disturbances
      qualifier: MONDO:0007739
      subject_extension: human immature dental pulp stem cells
    - subject: Intravenous infusion
      predicate: TREATS
      object: HP:0100543
      qualifier: MONDO:0007739
      subject_extension: human immature dental pulp stem cells
named_entities:
  - id: MONDO:0007739
    label: Huntington disease (HD)
  - id: HP:0001268
    label: Cognitive decline
  - id: CHEBI:76720
    label: Antisense oligonucleotides
  - id: HP:0002180
    label: neurodegeneration
  - id: MAXO:0001001
    label: gene therapies
  - id: MAXO:0000882
    label: Behavioral interventions
  - id: HP:0002315
    label: headache
  - id: CHEBI:134738
    label: laquinimod
  - id: CHEBI:4903
    label: ethinylestradiol
  - id: CHEBI:6443
    label: levonorgestrel
  - id: MONDO:0002602
    label: Central nervous system disorders
  - id: CHEBI:3962
    label: Curcumin
  - id: CHEBI:50803
    label: nanoparticles
  - id: MONDO:0005071
    label: Neurological Disorders
  - id: MAXO:0000647
    label: Chemotherapy
  - id: HP:0100543
    label: Cognitive impairment
  - id: HP:0012174
    label: glioblastoma
  - id: MONDO:0005109
    label: HIV
  - id: MONDO:0005559
    label: Neurodegenerative diseases
  - id: CHEBI:16243
    label: quercetin
  - id: CHEBI:27881
    label: resveratrol
  - id: CHEBI:75095
    label: chrysin
  - id: CHEBI:28821
    label: piperine
  - id: CHEBI:17620
    label: ferulic acid
  - id: CHEBI:78330
    label: huperzine A
  - id: CHEBI:16118
    label: berberine
  - id: CHEBI:2979
    label: baicalein
  - id: CHEBI:28230
    label: hesperetin
  - id: CHEBI:26536
    label: retinoic acid
  - id: HP:0000708
    label: Behavioral symptoms
  - id: MAXO:0001298
    label: therapy
  - id: MAXO:0009003
    label: Preimplantation genetic testing (PGT-M)
  - id: MONDO:0016621
    label: Juvenile Huntington Disease
  - id: HP:0000709
    label: psychosis
  - id: HP:0011951
    label: aspiration pneumonia
  - id: HP:0000716
    label: depression
  - id: MAXO:0000065
    label: aerobic exercises
  - id: MAXO:0000487
    label: clinical assessments
  - id: MAXO:0000387
    label: muscle biopsy
  - id: HP:0012531
    label: pain
  - id: HP:0100021
    label: Cerebral palsy
  - id: HP:0001915
    label: Aplastic anemia
  - id: HP:0002072
    label: Chorea
  - id: CHEBI:9467
    label: Tetrabenazine
  - id: MAXO:0000011
    label: Physical therapy
  - id: HP:0000739
    label: anxiety
  - id: CHEBI:7872
    label: oxytocin
  - id: CHEBI:9937
    label: vasopressin
  - id: HP:0033429
    label: neuroinflammation
  - id: MAXO:0000079
    label: genetic counseling
  - id: CHEBI:149681
    label: computer adaptive test (CAT)
  - id: MAXO:0000016
    label: Cell Therapy
  - id: MONDO:0005314
    label: Relapsing-remitting multiple sclerosis (RRMS)
  - id: HP:0011227
    label: elevated CRP
  - id: HP:0005268
    label: Spontaneous abortion
  - id: MAXO:0000021
    label: Palliative care
  - id: CHEBI:16348
    label: 3-nitropropionic acid (3-NP)
  - id: MAXO:0000068
    label: Transplantation
  - id: HP:0002344
    label: Progressive neurodegeneration
  - id: MONDO:0008199
    label: Parkinson disease (PD)
  - id: HP:0002527
    label: falls
  - id: CHEBI:25016
    label: Phosphate-buffered saline (PBS)
  - id: CHEBI:33385
    label: Tyrosine Hydroxylase (TH)
  - id: HP:0000657
    label: Ocular Motor Apraxia
  - id: HP:0025464
    label: Oxidative stress
  - id: HP:0003287
    label: Mitochondrial dysfunction
  - id: HP:0002511
    label: Alzheimer's disease
  - id: HP:0040141
    label: Tardive dyskinesia
  - id: HP:0001297
    label: Stroke
  - id: HP:0000618
    label: Blindness
  - id: HP:0001658
    label: Myocardial infarction
  - id: HP:0001824
    label: weight loss
  - id: CHEBI:27314
    label: water-soluble vitamins
  - id: CHEBI:46662
    label: minerals
  - id: HP:0002446
    label: Astrogliosis
  - id: HP:0000737
    label: Irritability
  - id: HP:0000741
    label: Apathy
  - id: HP:0012743
    label: abdominal obesity
  - id: CHEBI:145810
    label: Insulin
  - id: CHEBI:50826
    label: Silver nanoparticles (Ag-NPs)
  - id: CHEBI:36751
    label: PCA
  - id: MAXO:0000943
    label: Deep brain stimulation (DBS)
  - id: CHEBI:15765
    label: Levodopa
  - id: MONDO:0005180
    label: Parkinson's disease
  - id: CHEBI:51232
    label: Hoechst 33342
  - id: CHEBI:51240
    label: propidium iodide
  - id: CHEBI:30452
    label: TES
  - id: CHEBI:9754
    label: Tris
  - id: HP:0000238
    label: Hydrocephalus
  - id: MAXO:0001351
    label: rehabilitation (occupational therapy)
  - id: HP:0002093
    label: respiratory insufficiency
  - id: HP:0001262
    label: somnolence
  - id: CHEBI:29237
    label: Deuterium
  - id: CHEBI:38697
    label: Anthocyanins
  - id: CHEBI:15889
    label: Sterols
